Clinical Trials Logo

Filter by:
NCT ID: NCT03545087 Withdrawn - Renal Insufficiency Clinical Trials

A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

Start date: June 2018
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment. Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.

NCT ID: NCT03544788 Withdrawn - Venous Leg Ulcer Clinical Trials

Evaluation of Cirvo™ Mobile Compression Device for Treatment of Venous Leg Ulcers

HEAL I
Start date: June 30, 2019
Phase: N/A
Study type: Interventional

This study in venous leg ulcer (VLU) patients will evaluate the use of Cirvo™ therapy for the treatment of VLU when applied for a minimum of two hours daily for up to 12 weeks.

NCT ID: NCT03544073 Withdrawn - Infertility Clinical Trials

GnRH Agonist at Embryo Transfer: IVF Outcomes

GRAET
Start date: April 15, 2019
Phase: Phase 3
Study type: Interventional

In ART (assisted reproductive technology) cycles, embryos are transferred to a woman's uterus after in-vitro fertilization (IVF) in a laboratory. Usually, hormones (progesterone) are given to the patient after transferring the embryo, as a supplement, in order to mimic the natural hormones that would normally be secreted in an unassisted pregnancy. This study will identify whether additional gonadotropin-releasing hormone (GnRH-agonist) administration, a natural hormone secreted from the hypothalamus, will improve the clinical pregnancy and live birth rates when using IVF.

NCT ID: NCT03544034 Withdrawn - Adverse Drug Event Clinical Trials

Partnering With Patients for Improving Medication Safety During Transitions of Care: Implications for Work System Design

Start date: December 2019
Phase: N/A
Study type: Interventional

This project is to develop, implement, pilot evaluate, and disseminate a medication safety program (HomeTeam) that consolidates strategies to help patients by partnering with patients and their informal caregivers during transitions from hospital to home. Care transitions, especially from hospital to home, are high-risk periods for medication errors, and are frequently associated with serious adverse drug events (ADEs) and preventable readmissions. Older adults with multi-morbid conditions who have complex medication regimes are especially prone to these risks. Patients and family caregivers may experience a dramatic transition in roles and responsibilities immediately after hospital discharge. Patients and family caregivers are relatively passive recipients in their care and medication management in the hospital, but when patients arrive at home, patients have the primary responsibility for their care and medication use (with professional care providers switching to a 'supporting' function). Although this significant transition in the nature and intensity of patient work needs to be managed actively, often patients and family members are not adequately engaged and prepared in the hospital, and not effectively supported for safe medication use after hospital discharge. More specifically, patients and family members may not understand essential steps in the management of their condition, and have difficulty contacting appropriate health care practitioners for guidance. Although most organizations deploy multiple layers of interventions for improving care transitions, reducing postdischarge adverse drug events (ADEs), 30-day readmissions and emergency department (ED) visits, their impact to date has been small, and there remains significant and urgent need to fundamentally redesign the hospital-to-home care transition process. Investigators believe that one practical and potentially effective way for this 'much-needed' redesign is through engaging and supporting patients and families in safe medication use. Investigators' proposed program 'HomeTeam' will contain evidence-based tools and methods for engaging patients and shifting culture towards a truly patient-centered care for medication safety.

NCT ID: NCT03543033 Withdrawn - Clinical trials for Lumbar Radiculopathy

Preoperative Corticosteroid Epidural Injection and Lumbar Decompression Surgery Outcomes

Start date: September 10, 2018
Phase: N/A
Study type: Interventional

This randomized control trial will compare opioid use, pain, and functional outcomes following decompression surgery for single-level lumbar radiculopathy in patients who undergo placement of corticosteroid epidural injection within 2 weeks prior to surgery compared to those who do not. The hypothesis of this study is that patients who receive the preoperative corticosteroid injection will have less reduced postoperative opioid use, as well as earlier mobilization, reduced length of stay, and faster return to work compared to control patients who do not receive the injection.

NCT ID: NCT03537716 Withdrawn - Fat Burn Clinical Trials

Fat Reduction Induced by Magnetic Device - Ultrasonographic Evaluation

Start date: December 15, 2017
Phase: N/A
Study type: Interventional

The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and four follow-up visits, 1 month, 3, 6 and 12 months after the final treatment. At the baseline visit photographs of the abdomen will be taken. In addition, adipose/muscle layer thickness will be measured with the ultrasound and the subject's weight will be recorded. In addition, at the last therapy visit, subjects will receive Subject Satisfaction and Therapy Comfort Questionnaires to fill in. Safety measures will include documentation of adverse events (AE) including subject's experience of pain or discomfort after the procedure. Following each treatment administration and at the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment. Post-procedure evaluation (follow-up visits) will be conducted 1 month, 3, 6 and 12 months after the final treatment. An ultrasound imaging and weight measure will be conducted. Also, subject's satisfaction will be noted. During the first (1 month), third (6 months) and last (12 months) follow-up visits, photographs of abdomen will be taken.

NCT ID: NCT03536208 Withdrawn - Pancreatic Cancer Clinical Trials

Biological Effect of Warfarin on Pancreatic Cancer

Start date: May 15, 2019
Phase: Early Phase 1
Study type: Interventional

This study aims to asses the effect of warfarin on markers of AXL pathway in patients with pancreatic adenocarcinoma.

NCT ID: NCT03536182 Withdrawn - Clinical trials for Locally Advanced Pancreatic Adenocarcinoma

Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

CIPHER
Start date: May 29, 2019
Phase: Phase 3
Study type: Interventional

To determine if carbon ion radiotherapy improves overall survival versus photon therapy in patients with locally advanced, unresectable pancreatic cancer

NCT ID: NCT03534388 Withdrawn - Clinical trials for Arterial Bypass Graft Surgery

A Feasibility Study to Evaluate Skin Cleansing With a Sodium Hypochlorite Wash

Start date: May 10, 2018
Phase: N/A
Study type: Interventional

Feasibility study in approximately 20 subjects to investigate the rate of infection with subjects undergoing elective lower extremity arterial bypass graft surgery or femoral endarterectomy. The subjects are instructed to shower with the sodium hypochlorite body wash daily, or as modified by the physician, for 5 of the 7 days leading to their surgery.

NCT ID: NCT03534219 Withdrawn - Acute Otitis Media Clinical Trials

Efficacy of the EarPopper Device in Children With Recurrent Otitis Media

Start date: July 24, 2018
Phase: N/A
Study type: Interventional

This is a randomized controlled clinical trial evaluating the efficacy of the EarPopper device (EP) in the reduction of episodes of acute otitis media (AOM) in children with recurrent otitis media. The control arm will be observational. The intervention arm will have the EP used.